Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

KalVista Announces Initiation of a Phase 1 Clinical Trial of KVD818 for the Treatment of Hereditary Angioedema

11 August 2016: Salisbury, UK & Cambridge USA – KalVista Pharmaceuticals today announced the dosing of the first subject in a first-in-human clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally delivered KVD818 in healthy volunteers.  A KalVista discovery, KVD818 is a novel, potent, and selective inhibitor of plasma kallikrein in development for the prevention of attacks of edema in patients with hereditary angioedema (HAE).

Read the rest of entry »

SynbiCITE and Rainbow Seed Fund Announce New £200k Competition for Engineering Biology

11 August 2016: London, UK - Bio-start, an annual competition designed to bolster UK companies aiming to solve significant global problems through synthetic biology has been launched.

Read the rest of entry »

PCI to Host Free Webinar on the Development and Manufacturing of Highly Potent Molecules

11 August 2016: Philadelphia, USA –  The successful development and manufacturing of highly potent molecules is the theme of the next free, specialist webinar from leading pharmaceutical outsourcing provider PCI Pharma Services (Thursday, September 8, 10am EDT / 3pm GMT).

Read the rest of entry »

Summit Reports Positive Phase 1 Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid

Oxford, UK,  - Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, today reports Phase 1 clinical trial results that show a new formulation of ezutromid (referred to as 'F6') achieved a greater than six-fold increase in maximum plasma levels in DMD patients compared to those achieved with the current clinical formulation (referred to as 'F3') with only two fifths of the dose.

Read the rest of entry »

Global Cooperation Feasibility Studies: Apply for Funding

UK businesses could win a share of £1.2 million to carry out short, international cooperation feasibility studies. UK businesses looking to create international business networks can apply for funding of up to £21,000. This funding is to enable commercial research and innovation partnerships. It will also help businesses explore ideas for future collaboration.

Read the rest of entry »

MD Anderson Cancer Center Demonstrates Clinical Applicability of ANGLE's "Blood Biopsy" Technology

04 August 2016: Guildford, UK & Houston, USA - ANGLE plc, the specialist medtech company, announces a poster presentation by researchers from the University of Texas MD Anderson Cancer Center describing clinically-relevant results from a study using its lead product, the Parsortix cell separation system, to harvest breast cancer cells in blood for subsequent molecular characterisation. The poster was presented at the American Association for Clinical Chemistry Annual Meeting on 2 August 2016.

Read the rest of entry »

Chronos Therapeutics Strengthens Management Team with Appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl as Vice Presidents of Pre-Clinical Development

04 August 2016: Oxford, UK - Chronos Therapeutics Ltd, the private biotech company focused on ageing diseases, brain and nervous system disorders, today announced the appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl, as Vice Presidents of Pre-Clinical Development.

Read the rest of entry »

PCI Pharma Services Welcomes Two New Business Development Executives to Support its Growing US Market

03 August 2016: Cardiff, UK & Philadelphia, USA – Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the appointment of Sue Ritchie and Fred Schulze to its US sales team, with business development responsibility for PCI’s expanding global development and manufacturing capability.

Read the rest of entry »

Finalists Announced for OBN Awards 2016

03 August 2016: Abingdon, UK, OBN Ltd, the membership organisation supporting the UK’s innovative life sciences companies, today announces the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health. The OBN Awards remain proudly independent, celebrating innovation and achievement across the UK life sciences industry and recognising achievements from emerging to late stage R&D companies as well as life sciences investors.

Read the rest of entry »

Oxford Immunotec Reports Second Quarter 2016 Financial Results

02 August 2016: Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced second quarter 2016 financial results.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.